二甲双胍使用与青光眼风险:系统综述与荟萃分析
该研究系统检索了截至2025年6月16日的观察性队列研究,纳入12项回顾性队列(n=1,247,325),评估二甲双胍使用与青光眼发病风险的关联。粗分析OR=0.96(95%CI 0.87-1.06)无显著关联,但敏感性分析及时间-事件分析显示风险适度降低(aHR=0.88,95%CI 0.80-0.96),证据确定性从中等到极低不等。
要点
- 粗分析未显示二甲双胍与青光眼风险显著相关(OR=0.96,95%CI 0.87-1.06)。
- 时间-事件分析显示二甲双胍使用者青光眼风险适度降低(aHR=0.88,95%CI 0.80-0.96)。
- 证据确定性从极低(对照分析)到中等(时间-事件分析)不等。
核心结论
- 观察性队列中,粗分析未发现二甲双胍使用与青光眼风险降低相关,但敏感性分析和时间-事件分析提示可能具有保护作用。
研究设计与样本
- 系统综述与荟萃分析,纳入12项回顾性队列研究,共1,247,325例受试者(二甲双胍使用者732,423例,对照513,292例)。
- 检索PubMed、Scopus、Web of Science和Google Scholar截至2025年6月16日,方案注册于PROSPERO(CRD420250655975)。
- 使用Newcastle-Ottawa量表评估偏倚风险,随机效应模型合并二分类结局(OR)和时间-事件结局(HR),采用GRADE框架评级证据确定性。
主要发现
- 粗合并OR=0.96(95%CI 0.87-1.06;I²=79.14%;低确定性),无显著关联。
- 剔除使用非二甲双胍活性对照的研究后,敏感性分析OR=0.92(95%CI 0.87-0.98;低至中等确定性)。
- 时间-事件分析(4项研究)未调整HR=0.86(95%CI 0.79-0.93;I²=0%;中等确定性),调整后aHR=0.88(95%CI 0.80-0.96;I²=0.01%;中等确定性)。
关键数值与推荐
- 纳入标准:比较二甲双胍使用者与非使用者或其他降糖药使用者的青光眼发病率。
- 主要结局:二分类结局合并OR,时间-事件结局合并HR。
- 亚组分析:混杂调整方法和对照类型。
- 证据确定性:粗OR为低确定性;敏感性分析OR为低至中等确定性;未调整HR为中等确定性;调整后aHR为中等确定性;对照分析为极低确定性。
临床怎么用
- 对于糖尿病患者,二甲双胍使用可能与青光眼风险适度降低相关,但证据确定性不高,需结合临床判断。
- 时间-事件分析提示的保护作用在调整混杂因素后仍存在,但粗分析无显著关联,临床决策应谨慎。
局限性
- 纳入研究均为回顾性队列,存在残余混杂可能。
- 粗分析异质性较高(I²=79.14%)。
- 证据确定性总体不高,对照分析为极低确定性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
TOPIC: To evaluate whether metformin use is associated with a reduced risk of developing glaucoma. CLINICAL RELEVANCE: Glaucoma is a leading cause of irreversible blindness worldwide. Identifying systemic medications that may modify glaucoma risk could have important implications for prevention strategies in patients with diabetes, a population frequently treated with metformin. METHODS: This systematic review and meta-analysis of observational cohort studies, registered on PROSPERO (CRD420250655975), was done through PubMed, Scopus, Web of Science, and Google Scholar until June 16, 2025. Eligible studies compared glaucoma incidence among metformin users versus nonusers or users of other antidiabetic drugs (ADDs). Risk of bias was assessed using the Newcastle-Ottawa Scale. Binary outcomes were pooled using random-effects models to calculate odds ratios (ORs), and time-to-event outcomes were synthesized using hazard ratios (HRs). Subgroup analyses explored confounder adjustment methods and comparator types. Certainty of evidence was graded using GRADE framework. RESULTS: Twelve retrospective cohort studies (n = 1,247,325; 732,423 metformin users; 513,292 controls) were included. The pooled crude OR showed no association between metformin use and glaucoma risk (OR = 0.96; 95% CI, 0.87-1.06; I² = 79.14%; low certainty). A leave-one-out sensitivity analysis excluding a study with a nonmetformin active comparator resulted in a modest but significant reduction in risk (OR = 0.92; 95% CI, 0.87-0.98; low to moderate certainty). No effect modification was detected by the confounder adjustment method (propensity-score matched vs regression; P = .20; low certainty) or comparator type (no metformin vs other ADDs; P = .34; very low certainty). The follow-up duration did not significantly modify the effects. Four studies contributed time-to-event analyses: pooled unadjusted HR indicated a lower risk among metformin users (HR = 0.86; 95% CI, 0.79-0.93; I² = 0%; moderate certainty), which persisted in adjusted models (aHR = 0.88; 95% CI, 0.80-0.96; I² = 0.01%; moderate certainty). There was no evidence of small-study effects (Egger's P = .955). CONCLUSION: Across observational cohorts, metformin use was not associated with a reduced glaucoma risk in crude analyses; however, sensitivity analyses suggested a possible protective effect. Time-to-event analyses consistently demonstrated a modest reduction in glaucoma risk, supported by moderate-certainty evidence after adjusting for confounders. Overall, certainty of evidence ranged from very low (comparator analyses) to moderate (time-to-event analyses).
引用
- Abdelaal A, Abu Serhan H, Alsaadi M, et al. Metformin Use and Risk of Glaucoma: A Systematic Review and Meta-Analysis. Am J Ophthalmol. 2026. PMID: 41812849. doi:10.1016/j.ajo.2026.03.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。